07:00 , Aug 2, 2010 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cynapsus deal

Adagio granted Cynapsus (formerly Cannasat Therapeutics Inc. ) an exclusive option for exclusive, worldwide rights to develop and commercialize Adagio's APL-130277 . The small molecule dopamine receptor agonist is an oral formulation of apomorphine to...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Company News

Cannasat, IntelGenx deal

IntelGenx signed a letter of intent to acquire a 50% stake in Relivar , a sublingual tablet formulation of dronabinol (delta-9-tetrahydrocannabinol, THC). Under the letter, IntelGenx also would receive an exclusive, worldwide license to develop...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Adagio Pharmaceuticals, Cannasat deal

The companies signed a letter of intent granting Cannasat an exclusive option to obtain exclusive, worldwide rights to develop and commercialize Adagio's APL-130277 to treat Parkinson's disease. Cannasat will have a 12-month option period to...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Cannasat management update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario   Business: Drug delivery, Neurology   Hired: Anthony Giovinazzo as president and CEO, formerly president of the Neuroscience Partners Fund; he replaces David Hill, who remains vice chairman  ...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Financial News

Cannasat completes private placement of units

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario   Business: Drug delivery, Neurology   Date completed: 8/31/09   Type: Private placement of units   Raised: C$178,900 (US$161,618)   Units: 1.8 million   Price: C$0.10 (unit)   Shares...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Financial News

Cannasat completes private placement of units

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario   Business: Drug delivery, Neurology   Date completed: 8/6/09   Type: Private placement of units   Raised: C$750,950 (US$693,728)   Units: 7.5 million   Price: C$0.10 (unit)   Shares...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

CAT 310: Phase Ib started

The companies began an open-label, Canadian Phase Ib trial in healthy volunteers to evaluate oral CAT 310 vs. Marinol dronabinol from Solvay S.A. (Euronext:SOLB, Brussels, Belgium). Cannasat and IntelGenx are co-developing cannabinoid-based products using IntelGenx's...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Cannasat, Prairie Plant Systems Inc. deal

Cannasat divested its 12% equity stake in Prairie for $1.1 million, the amount Cannasat paid for the shares in 2004. The companies also ended their 2004 collaboration to develop and market cannabinoid compounds to treat...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Company News

Cannasat board of directors update

Cannasat Therapeutics Inc. (TSX-V:CTH), Toronto, Ontario   Business: Neurology   Appointed: Julia Levy, co-founder of QLT Inc.   Resigned: Lorne Gertner  ...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Cannasat, IntelGenx deal

The partners expanded a November 2006 deal to co-develop cannabinoid-based products using IGXT's oral transmucosal drug delivery technology. The original deal focused on the development of CTH's CAT 310 to treat nausea in cancer patients...